Tagged with IT

Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…

Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…

Greece General Manager of the Hellenic Association of Pharmaceutical Companies (SFEE), Mihalis Himonas speaks about his role spearheading Greece’s main pharma association, the contribution of the pharma industry to GDP, market access challenges, and solutions for creating a sustainable healthcare environment. As the organization representing the united voice of the pharmaceutical…

Ireland Sorcha McKenna, Partner at McKinsey & Company in Ireland, discusses the current trends in the Irish healthcare and life sciences sector, the potential behind both tech and integrated care for the industry, as well as some of the biggest evolutions she has seen during her 14-year career with the company.…

Philippines The election of maverick former mayor of Davao, Rodrigo Duterte to the Filipino presidency in May 2016 represented a dramatic departure from politics as usual and raised interesting questions about future health policy in south East Asia’s second most populous country. “A human approach to development that leaves no citizen…

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments.   What other mid-sized multinational pharmaceutical companies present in over 80…

Switzerland Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause of MS, as well as the reasons for choosing Geneva when working with multiple sclerosis. Following 15 years of research performed by French-based Institut Mérieux and INSERM, GeNeuro was…

Ireland Dr. Terry McWade, CEO of Valitacell, discusses the founding of his company, the ground-breaking technology they are producing, and how this technology can help to bring new biologic medications to market faster and more cost-effectively. Having just won the Seedcorn Competition as well as being placed on the list of…

Switzerland Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions. Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to…

Switzerland The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to create value for companies in the life science industry. You first joined NNIT in 2010; you then moved to the FMCG sector for a few…

Switzerland Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company maintains its market leader position, and working with both national and international partners to create better products for its customers and a more efficient insurance system. With 1.9 million policy takers…